Abstract
BackgroundFrom 2014 to 2017, more than 1000 diagnostic companies were launched, securing more than US$10 billion in investment.MethodsWe performed an in-depth exploration of 28 diagnostic companies to differentiate successful and failed startups, plus a third ‘Zombie’ state where companies have achieved financial solvency but without long-term viability.ResultsFrom these data, we created a five-phase, 13-item framework indicating the corporate health of a diagnostic company as it progresses from conception to commercialisation. We found 6 successful companies, 14 failures and 8 Zombies. On a scale of 0–26 points (two points per item), successful companies averaged 24.5 points (range 22–26), failures averaged 4.5 (range 0–16) and Zombies averaged 12.3 (range 3–23) (p<0.001). To determine if there was any predictivity to this framework, we looked at only the first two phases (concept and feasibility/planning) of progress and found a distinct gradient in success potential based solely on these first two phases.ConclusionOur five-phase framework generated a score that could predict diagnostic companies more likely to successfully and sustainably enter the market from those more likely to fail.
Reference23 articles.
1. New diagnostic tests: more harm than good
2. Jain KK . “Development of Personalized Medicine,” Textbook of Personalized Medicine. New York: Springer Science+Business Media, 2015.
3. De Winter A . Why it’s a good year for diagnostic startups. Available: https://medcitynews.com/2017/08/good-year-diagnostics-startups/ [Accessed 31 May 2019].
4. New thinking on clinical utility: hard lessons for molecular diagnostics;Peabody;Am J Manag Care,2014
5. Timmerman L . Molecular diagnostics are in a rut. The industry needs the FDA. Available: https://xconomy.com/national/2014/02/17/molecular-diagnostics-are-in-a-rut-the-industry-needs-the-fda/ [Accessed 31 May 2019].